Overview#
TD Cowen has raised its price target for Kiniksa Pharmaceuticals Inc. (NASDAQ: KNSA) from $60 to $65, while maintaining a Buy rating on the stock. This adjustment comes in light of impressive sales figures for Kiniksa's drug, Arcalyst.
Strong Sales Performance#
In the first quarter of 2026, Arcalyst generated sales of $214 million, marking a 6% increase from the previous quarter and a remarkable 56% increase compared to the same period last year. These results exceeded analysts' expectations by 5%, despite the typical challenges that come with the first quarter of the year. The strong performance has contributed to a 103% rise in Kiniksa’s stock price over the past year, with shares currently trading at $51.46.
Financial Health#
TD Cowen highlighted that Kiniksa has more cash than debt on its balance sheet, which supports its ongoing growth. The firm described the recent quarter as the best for Arcalyst in terms of all performance metrics. The new price target is based on a valuation method that considers future cash flows, reflecting the anticipated continued success of Arcalyst.
Future Outlook#
Looking ahead, TD Cowen expects to see Phase II data for KPL-387 in the latter half of 2026. Kiniksa's recent financial results also showed earnings per share (EPS) of $0.27, surpassing the forecasted $0.21 by 28.57%. Additionally, the company's revenue of $214.3 million exceeded the expected $207.12 million, underscoring its strong market position. While there are no updates on mergers or acquisitions, the focus remains on Kiniksa's solid financial performance and its implications for investor interest.